Corteria Pharmaceuticals announces initiation of Phase 1 study to evaluate CRF2 agonist COR-1167 for treatment of worsening heart failure menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ Invizius Limited ("Invizius"), a biotechnology company developing second generation therapies for a range of complement-driven autoimmune and.